echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > STTT makes new progress!

    STTT makes new progress!

    • Last Update: 2022-06-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    iNature functional IL-10-secreting B cells are considered functional regulatory B (Breg) cells; however, direct evidence on the phenotype, regulation, and functional and clinical relevance of human IL-10-secreting Breg cells is still lacking
    .

    On April 18, 2022, Chen Yun from Nanjing Medical University, Wang Xuehao and Kuang Dongming from Sun Yat-Sen University jointly published an online article entitled "c-Myc-driven glycolysis polarizes functional regulatory B cells that trigger pathogenic inflammatory inflammatory disease" in Signal Transduction and Targeted Therapy (IF=18).
    Responses", which demonstrated that despite the anti-inflammatory effects of IL-10 itself, IL-10+ functional Breg cells from patients with systemic lupus erythematosus (SLE) displayed aggressive inflammatory features
    .

    These features shift its function from inducing CD8+ T cell tolerance to inducing pathogenic CD4+ T cell responses
    .

    Functional Breg cells polarized by environmental factors such as CPG-DNA or directly isolated from SLE patients mainly exhibit a CD24intCD27−CD38−CD69+/hi phenotype distinct from their precursors
    .

    Mechanistically, MAPK/ERK/P38-triggered sequential oncogenic c-Myc upregulation and enhanced glycolysis are necessary for the generation and maintenance of functional Breg cells
    .

    Consistently, strategies to eliminate ERK, p38, c-Myc and/or cellular glycolytic activity can effectively abolish the pathogenic effects triggered by functional Breg cells
    .

    On March 9, 2022, the team of Chen Yun from Nanjing Medical University published a research paper titled "Gut microbiota-derived short-chain fatty acids regulates group 3 innate lymphoid cells in hepatocellular carcinoma" in Hepatology (IF=17).
    Modification of bacteria, alteration of SCFAs, reduction of infiltration of IL17A-producing ILC3s, and combination with immune checkpoint inhibitors will contribute to the clinical treatment of HCC (click to read)
    .

    On March 4, 2022, Chen Yun and Dai Juncheng of Nanjing Medical University jointly published a research paper entitled "Single-cell profiling of human CD127+ innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma" in Hepatology (IF=17).
    Single-cell RNA sequencing (scRNA-seq) analysis of sorted hepatic ILC cells from human HCC patients was performed and validated using flow cytometry, multiplex immunofluorescence staining, and functional experiments
    .

    Furthermore, this study applied a selection strategy to enrich the ILC population in HCC samples to investigate the effect of B cells on the immune response of ICOS+ ILC2 cells
    .

    Dysregulation of ILCs manifests as changes in cell numbers or subpopulation ratios in HCC
    .

    Seven subsets of 3,433 ILCs were identified as having unique properties, with ICOS+ILC2a being preferentially enriched in HCC and associated with poor prognosis
    .

    In conclusion, this study provides new insights into B cell-driven innate type 2 inflammation and a potential strategy for HCC immunotherapy (click to read)
    .

    Regulatory B (Breg) cells are now considered suppressor cells that support immune tolerance
    .

    A common feature of all described Breg subsets is their ability to release IL-10, and IL-10 release is widely used to define functional Breg cells
    .

    However, in addition to producing IL-10, Breg cells express other molecules (eg, PD-L1, FasL, and granzyme B) that cause additional pathological effects
    .

    Therefore, IL-10 is necessary, but not sufficient, for the activity of Breg cells
    .

    Studies have established that in healthy individuals and patients, immature transitional CD24hiCD38hi B cells versus mature CD24hiCD27+ B cells represent important cellular sources of peripheral Breg cells
    .

    Notably, the appearance of CD24hiCD38hi or CD24hiCD27+ phenotypes on B cells does not necessarily reflect their function
    .

    Indeed, in patients with autoimmune diseases, CD24hiCD38hi and CD24hiCD27+ B cells hardly directly produce immunosuppressive functions
    .

    Direct evidence supporting the role of functional Breg cells in the immunopathogenesis of human disease is still lacking
    .

    Furthermore, a related question that must be addressed in this context is whether functional Breg cells exhibit unique functions that differ from known functions, and if so, how B cells exert these effects
    .

    Metabolic reprogramming is emerging as a key process that reshapes immune cell differentiation and function
    .

    Naive and memory B cells employ oxidative phosphorylation (OXPHOS) to provide basal energy requirements for metabolic quiescence
    .

    In contrast, high-intensity glycolysis, together with aggressive OXPHOS, controls antibody secretion by effector B cells (also known as plasma cells), a process that relies on active glucose and amino acid uptake mechanisms
    .

    Notably, although not directly related to B cells, glycolysis has also been identified as a potent activator of inflammatory responses, and OXPHOS has been implicated in anti-inflammatory responses and immune tolerance
    .

    To date, the precise metabolic program of functional Breg cells that secrete IL-10 under pathological conditions is unknown
    .

    In other words, assessing the metabolic program of functional Breg cells under pathological conditions is critical for understanding the polarization and functional status of these cells in immune pathogenesis
    .

    Phenotypic characterization of IL-10-secreting Breg cells in SLE (Figure from Signal Transduction and Targeted Therapy) Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease characterized by extensive inflammation and tissue damage , can affect any part of the body
    .

    In SLE patients, deficits in suppressing cell function are necessary to enhance inflammation and the active stage of the disease
    .

    It is postulated that Breg cells are a protective factor that hinders inflammatory responses based on their ability to produce IL-10
    .

    However, by exploring the phenotypic characteristics and function of IL-10-secreting B cells in SLE patients, this study found that functional Breg cells act primarily as causative factors, but not as inflammation suppressors
    .

    Functional Breg cells triggered by SLE pathological factors, such as CPG-DNA, exhibit a previously unrecognized CD24intCD27−CD38−CD69+/hi phenotype while producing numerous inflammatory mediators, a process triggered by MAPK/ERK/P38 signaling in a continuous manner Oncogenic c-Myc upregulation and enhanced glycolysis
    .

    More importantly, this study demonstrates that these inflammatory signatures shift the functions of Breg cells from those that induce CD8+ T cell tolerance to those that induce inflammatory TH cell responses
    .

    Thus, inhibiting the activity of ERK, P38, c-Myc, or the glycolytic enzyme PFKFB3 in functional Breg cells from patients with SLE could effectively attenuate the polarization of pathogenic inflammatory TH cell subsets
    .

    Reference message: https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.